Elanco Animal Health Reports 2024 Earnings and 2025 Outlook

Elanco Animal Health ( (ELAN) ) has released its Q4 earnings. Here is a breakdown of the information Elanco Animal Health presented to its investors.

Elanco Animal Health Incorporated is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, enhancing value for farmers, pet owners, and veterinarians.

Elanco Animal Health reported its financial results for the fourth quarter and full year of 2024, showing a slight decline in revenue on a reported basis but an increase on an organic constant currency basis. The company also provided guidance for 2025, highlighting expectations for continued growth despite foreign exchange headwinds.

In the fourth quarter of 2024, Elanco’s revenue was $1,020 million, a 1% decrease on a reported basis but a 4% increase on an organic constant currency basis. The company reported a net loss of $8 million but achieved an adjusted net income of $72 million. For the full year, Elanco’s revenue was $4,439 million, with an adjusted EBITDA of $910 million, representing 20.5% of revenue. The company exceeded its innovation revenue target and launched several new products, reinforcing its diverse portfolio.

Looking ahead to 2025, Elanco maintains its revenue guidance, expecting growth to accelerate to mid-single digits on an organic constant currency basis. The company anticipates a foreign exchange headwind impacting revenue and adjusted EBITDA but remains confident in its strategic investments and innovation pipeline to drive future growth.

Elanco’s management remains optimistic about the company’s prospects, focusing on accelerating organic growth and improving earnings potential. Despite challenges, the company is committed to delivering long-term value and maintaining its leadership in the animal health industry.